Gene therapy shot could end frequent eye injections for wet AMD
NCT ID NCT05984927
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 24 times
Summary
This early-stage trial tests a one-time gene therapy injection (NG101) for wet age-related macular degeneration. The therapy uses a harmless virus to deliver a gene that makes a drug inside the eye, aiming to reduce the need for repeated anti-VEGF injections. About 20 adults aged 50-89 with active disease will receive a single subretinal injection and be monitored for safety and vision changes over several years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cincinnati Eye Institute
Cincinnati, Ohio, 45242, United States
-
Retina Consultants of Texas
Bellaire, Texas, 77401, United States
-
Sunnybrook Ophthalmology and Vision Services
Toronto, Ontario, M4N 3M5, Canada
-
Vancouver Coastal Health Research Institute
Vancouver, British Columbia, V5Z 3N9, Canada
-
Vitreous Retina Macula Specialists of Toronto
Toronto, Ontario, M8X 2X3, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NG101 gene therapy (a single injection into the eye using a harmless virus to deliver a drug-making gene)
What this could lead to
If it works, this could mean fewer anti-VEGF injections for wet AMD patients, potentially lasting years from one treatment.
What could go wrong
This is an early (phase 1/2a) small trial with only 20 people. Gene therapy carries risks like inflammation or vision loss, and long-term effects are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.